ROBERTS EIRY, Chief Medical Officer of Neurocrine Biosciences (NBIX), has demonstrated a clear selling bias in recent transactions, with no open-market purchases recorded in the past year. Since January 2024, Roberts has executed nine sales totaling $1.24 million, including a $222,636 disposition on January 31, 2025, followed by multiple February 2025 transactions ranging from $57,521 to $130,232. The activity contrasts with earlier acquisitions—primarily through derivative securities—notably four November 2024 transactions involving option exercises totaling approximately $600,000. All transactions center exclusively on NBIX, where Roberts has held an executive role. The pattern shows consistent divestment, with the most recent sales occurring February 10–14, 2025, amounting to $373,116. While derivative-related activity in late 2024 suggests prior equity accumulation, the absence of recent buys and sustained selling—particularly the $205,132 and $159,446 sales in January-February 2024—indicates a multiyear trend toward reducing exposure. The transactions represent routine disclosures without discretionary purchases, focusing on monetizing existing holdings rather than expanding them.
AI-assisted summary